Krebs Biochemicals & Industries Limited

BSE:524518 Stock Report

Market Cap: ₹2.2b

Krebs Biochemicals & Industries Past Earnings Performance

Past criteria checks 0/6

Krebs Biochemicals & Industries has been growing earnings at an average annual rate of 5.9%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 7% per year.

Key information

5.9%

Earnings growth rate

9.3%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate7.0%
Return on equityn/a
Net Margin-42.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Krebs Biochemicals & Industries makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:524518 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24507-2181750
30 Jun 24527-1961670
31 Mar 24504-1971710
31 Dec 23499-2081780
30 Sep 23460-2141730
30 Jun 23521-2191620
31 Mar 23521-2471650
31 Dec 22588-2911640
30 Sep 22715-3651670
30 Jun 22636-4321570
31 Mar 22597-4451600
31 Dec 21554-4021590
30 Sep 21432-3551560
30 Jun 21489-3111490
31 Mar 21527-2841690
31 Dec 20516-2751680
30 Sep 20495-2661660
30 Jun 20403-2801560
31 Mar 20324-2891600
31 Dec 19294-2791580
30 Sep 19332-2711620
30 Jun 19435-2231530
31 Mar 19467-2001580
31 Dec 18441-2201610
30 Sep 18528-1531650
30 Jun 18403-1701460
31 Mar 18327-1781240
31 Dec 17266-140920
30 Sep 1766-190630
30 Jun 1739-183610
31 Mar 1721-163670
31 Dec 1617-184630
30 Sep 1617-172610
30 Jun 1617-171570
31 Mar 164-166650
31 Dec 152-2641360
30 Sep 152-2461310
30 Jun 152-211890
31 Mar 150-60-100
31 Dec 140-1720
30 Sep 140-2470
30 Jun 140-37360
31 Mar 14020480
31 Dec 139-17570

Quality Earnings: 524518 is currently unprofitable.

Growing Profit Margin: 524518 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 524518 is unprofitable, but has reduced losses over the past 5 years at a rate of 5.9% per year.

Accelerating Growth: Unable to compare 524518's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 524518 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.4%).

Return on Equity

High ROE: 524518's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 13:27
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Krebs Biochemicals & Industries Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution